Denali Therapeutics (DNLI) Research & Development (2017 - 2026)
Denali Therapeutics (DNLI) reported Research & Development of $103.8 million for Q1 2026, down 10.65% year-over-year from $116.2 million in Q1 2025, and up 6.07% on a QoQ basis from $97.9 million in Q4 2025.
Denali Therapeutics (DNLI) has 10 years of Research & Development data on file, last reported at $103.8 million in Q1 2026.
- Quarterly Research & Development fell 10.65% year-over-year to $103.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $406.4 million (changed 0.18% YoY) and the FY2025 annual result came in at $418.8 million, up 5.63% from the prior year.
- Research & Development climbed to $103.8 million in Q1 2026 per DNLI's latest filing, from $97.9 million in the prior quarter.
- Across five years, Research & Development topped out at $128.8 million in Q1 2023 and bottomed at $86.1 million in Q1 2022.
- The 5-year median for Research & Development is $98.2 million (2024), against an average of $100.1 million.
- The widest annual swing landed in 2023, when Research & Development surged 49.62%; it then fell 16.92% in 2024.
- Tracing DNLI's Research & Development over 5 years: stood at $92.1 million in 2022, then increased by 17.04% to $107.8 million in 2023, then decreased by 7.44% to $99.8 million in 2024, then fell by 1.89% to $97.9 million in 2025, then climbed by 6.07% to $103.8 million in 2026.
- Per Business Quant, the three latest DNLI Research & Development figures stand at $103.8 million (Q1 2026), $97.9 million (Q4 2025), and $101.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -2.30 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.54 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 364.87 Mn |
| 10 | Denali Therapeutics | 3.82 Bn | 3.82 Bn | - | 103.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 103.85 Mn |
| Dec 31, 2025 | 97.91 Mn |
| Sep 30, 2025 | 101.95 Mn |
| Jun 30, 2025 | 102.70 Mn |
| Mar 31, 2025 | 116.23 Mn |
| Dec 31, 2024 | 99.79 Mn |
| Sep 30, 2024 | 98.24 Mn |
| Jun 30, 2024 | 91.40 Mn |
| Mar 31, 2024 | 107.02 Mn |
| Dec 31, 2023 | 107.80 Mn |
| Sep 30, 2023 | 89.74 Mn |
| Jun 30, 2023 | 97.52 Mn |
| Mar 31, 2023 | 128.82 Mn |
| Dec 31, 2022 | 92.11 Mn |
| Sep 30, 2022 | 87.79 Mn |
| Jun 30, 2022 | 92.74 Mn |
| Mar 31, 2022 | 86.10 Mn |
| Dec 31, 2021 | 67.88 Mn |
| Sep 30, 2021 | 71.56 Mn |
| Jun 30, 2021 | 65.71 Mn |
| Mar 31, 2021 | 60.21 Mn |
| Dec 31, 2020 | 54.74 Mn |
| Sep 30, 2020 | 53.70 Mn |
| Jun 30, 2020 | 53.15 Mn |
| Mar 31, 2020 | 51.02 Mn |
| Sep 30, 2019 | 52.54 Mn |
| Jun 30, 2019 | 51.88 Mn |
| Mar 31, 2019 | 37.40 Mn |
| Dec 31, 2018 | 39.91 Mn |
| Sep 30, 2018 | 30.32 Mn |
| Jun 30, 2018 | 52.13 Mn |
| Mar 31, 2018 | 20.82 Mn |
| Dec 31, 2017 | 18.47 Mn |
| Sep 30, 2017 | 18.52 Mn |
| Jun 30, 2017 | 19.00 Mn |
| Mar 31, 2017 | 18.47 Mn |